Cannabis Spray Effective For Refractory Back And Neck Pain Patients
People experiencing pain in the neck and/or back is very common around the world. Over 7.5% of the world’s global population suffers from lower back pain alone, and hundreds of millions more people suffer from varying levels of neck pain.
In addition to the pain experienced by suffering patients, which can be extreme in some cases, the costs of treating the ailments for both the patient and society are considerable. A study in 2017 found that just in the United States alone, neck and back conditions cost $88 billion a year.
An increasing number of suffering neck and back patients are turning to cannabis products for relief and a recent study in Australia found that cannabis spray in particular is an effective treatment method. Below is more about it via a news release from NORML:
Sydney, Australia: The oral administration of a cannabinoid spray containing standardized ratios of THC and CBD produces clinically significant reductions in pain among patients with chronic back and neck pain, according to open-label trial data published in the journal Medical Cannabis and Cannabinoids.
Australian researchers assessed the safety and efficacy of an oromucosal spray containing 10 mg of THC and 25 mg of CBD in a cohort of 28 patients with moderate to severe back or neck pain. Participants in the study were unresponsive to over-the-counter non-opioid analgesics. Patients administered escalating doses of the spray daily for four weeks.
Investigators documented decreases in patients’ pain at even the lowest doses. Patients experienced further reductions in pain and improvements in mood in a dose-dependent manner over the course of the trial. Overall, side-effects from the spray were mild and well-tolerated.
“There were significant reductions in pain [at] all doses,” authors concluded. “There was also a reduction in pain interference in all domains including general activity, mood, walking ability, normal work, relationships, sleep, and enjoyment of life by dose.”
Australian law permits physicians to authorize cannabis products to patients unresponsive to conventional prescription treatments.
Full text of the study, “Tolerability and efficacy of a 10:25 preparation of delta-9-tetrahydrocannabinol and cannabidiol for treatment of chronic back or neck pain: A multiple-dose escalation study,” appears in Medical Cannabis and Cannabinoids. Additional information on cannabis and chronic pain is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.
